CN101066952A - 晶体药物 - Google Patents

晶体药物 Download PDF

Info

Publication number
CN101066952A
CN101066952A CNA2007101123988A CN200710112398A CN101066952A CN 101066952 A CN101066952 A CN 101066952A CN A2007101123988 A CNA2007101123988 A CN A2007101123988A CN 200710112398 A CN200710112398 A CN 200710112398A CN 101066952 A CN101066952 A CN 101066952A
Authority
CN
China
Prior art keywords
wei
crystalline form
luo pin
type
luo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101123988A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·迪克曼
S·切姆伯卡
J·J·福尔特
R·F·亨赖
D·勒楚加－巴勒斯特罗斯
Y·牛
W·波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101066952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN101066952A publication Critical patent/CN101066952A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007101123988A 2000-03-30 2001-03-21 晶体药物 Pending CN101066952A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/538257 2000-03-30
US09/793536 2001-02-27
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018076882A Division CN1330639C (zh) 2000-03-30 2001-03-21 晶体药物

Publications (1)

Publication Number Publication Date
CN101066952A true CN101066952A (zh) 2007-11-07

Family

ID=27065762

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018076882A Expired - Lifetime CN1330639C (zh) 2000-03-30 2001-03-21 晶体药物
CNA2007101123988A Pending CN101066952A (zh) 2000-03-30 2001-03-21 晶体药物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB018076882A Expired - Lifetime CN1330639C (zh) 2000-03-30 2001-03-21 晶体药物

Country Status (22)

Country Link
EP (1) EP1268442A2 (no)
JP (1) JP2003529592A (no)
KR (1) KR100773258B1 (no)
CN (2) CN1330639C (no)
AR (2) AR033360A1 (no)
AU (3) AU5092001A (no)
BG (1) BG107165A (no)
BR (1) BR0109433A (no)
CA (1) CA2403635A1 (no)
CZ (1) CZ20023529A3 (no)
HU (1) HUP0302675A3 (no)
IL (1) IL151551A0 (no)
MX (1) MXPA02009559A (no)
MY (1) MY128296A (no)
NO (1) NO325005B1 (no)
NZ (1) NZ521183A (no)
PE (1) PE20011232A1 (no)
PL (1) PL359727A1 (no)
SA (2) SA06270303B1 (no)
SK (1) SK14832002A3 (no)
TW (1) TWI284640B (no)
WO (1) WO2001074787A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ES2459301T3 (es) * 2009-02-06 2014-05-08 Hetero Research Foundation Nuevos polimorfos de lopinavir
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
AR049560A2 (es) 2006-08-16
CZ20023529A3 (cs) 2003-02-12
BR0109433A (pt) 2004-08-10
NO20024679L (no) 2002-09-30
SA01220270B1 (ar) 2006-11-14
HUP0302675A3 (en) 2004-03-29
TWI284640B (en) 2007-08-01
NZ521183A (en) 2004-03-26
WO2001074787A2 (en) 2001-10-11
CA2403635A1 (en) 2001-10-11
PE20011232A1 (es) 2001-12-08
MY128296A (en) 2007-01-31
AU2006222711A1 (en) 2006-10-19
NO325005B1 (no) 2008-01-14
WO2001074787A3 (en) 2002-02-07
SA06270303B1 (ar) 2009-08-02
JP2003529592A (ja) 2003-10-07
IL151551A0 (en) 2003-04-10
MXPA02009559A (es) 2003-05-21
CN1422259A (zh) 2003-06-04
CN1330639C (zh) 2007-08-08
AU2001250920B2 (en) 2006-06-29
KR20030011807A (ko) 2003-02-11
EP1268442A2 (en) 2003-01-02
NO20024679D0 (no) 2002-09-30
PL359727A1 (en) 2004-09-06
KR100773258B1 (ko) 2007-11-05
BG107165A (bg) 2003-07-31
AU5092001A (en) 2001-10-15
SK14832002A3 (sk) 2003-02-04
AR033360A1 (es) 2003-12-17
HUP0302675A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
CN1146567C (zh) 奥氮平二水合物d
CN1043639C (zh) 新的哌啶化合物、其制备方法和含有它们的药用组合物
CN1668623A (zh) 一种拟多晶型hiv蛋白酶抑制剂
CN101052631A (zh) 结晶霉酚酸钠
CN1516699A (zh) 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的多晶型物
CN1282316A (zh) 用作神经氨酸酶抑制剂的取代环戊烷和环戊烯化合物
CN1699343A (zh) 盐酸多奈哌齐的多晶型物及其制备方法
CN1509174A (zh) 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9,－五烯的酒石酸盐
CN86100090A (zh) 萘衍生物的制备方法
CN1803137A (zh) 晶体的制备方法
CN1922179A (zh) 盐酸伐昔洛韦的结晶形式
CN1122036C (zh) 用于制备奥氮平的中间体和方法
CN1636993A (zh) 新的帕罗西汀盐酸盐无水合物的制备方法
CN1849304A (zh) 氟伐他汀钠晶形、制备它们的方法、包含它们的组合物及它们的使用方法
CN1018833B (zh) 烷基取代的苯并嗪并利福霉素衍生物制备方法
CN1229346C (zh) 丁苯哌丁醇的非对映体盐
CN1108657A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1894251A (zh) (6r)－l－赤型－四氢生物蝶呤二盐酸盐的晶型
CN1809529A (zh) 羧酸衍生物的药用盐
CN1035509A (zh) 头孢菌素类衍生物及其制备方法
CN101066952A (zh) 晶体药物
CN1665504A (zh) 新晶型的加替沙星
CN1222534C (zh) VI型5,6－二氯－2－(异丙基氨基)－1－(β－L－呋喃核糖基)－1H－苯并咪唑
CN1308342C (zh) 核糖取代的芳族化合物,其制备方法和作为药物的应用
CN1196686C (zh) 保存季铵盐的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071107